TECFIDERA efficacy across 2 pivotal trials and additional studies1,4-8

Explore efficacy

Data on newly diagnosed patients at
2 and 6 years7,8

Explore these analyses

Well-known safety across
2 pivotal trials1,4,5

Explore safety

24/7 patient support by phone on dosing, frequency, and managing common side effects

Explore Above MS™

87% first-line coverage2‡
$0 Copay for eligible patients

Explore access

Coverage may vary, and there is no guarantee of coverage.

DEFINE=Determination of the Efficacy and Safety of Oral Fumarate in Relapsing-Remitting MS4; CONFIRM=Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis.5

References: 1. TECFIDERA Prescribing Information, Biogen, Cambridge, MA. 2. Biogen, Data on file. 3. IMS NPA™. Number of prescriptions from weekly data (September 27, 2013-March 29, 2019). 4. Gold R, et al. N Engl J Med. 2012;367(12):1098-1107. Erratum in: N Engl J Med. 2012;367(24):2362. 5. Fox RJ, et al. N Engl J Med. 2012;367(12):1087-1097. Erratum in: N Engl J Med. 2012;367(17):1673. 6. Gold R, et al. Mult Scler. 2017;23(2):253-265. 7. Gold R, et al. Mult Scler. 2015;21(1):57-66. 8. Gold R, et al. Neurol Ther. 2016;5(1):45-47.